A Preview Of Blueprint Medicines's Earnings
Portfolio Pulse from Benzinga Insights
Blueprint Medicines (NASDAQ:BPMC) is set to release its latest quarterly earnings report on August 2, 2023. Analysts estimate an earnings per share (EPS) of $-2.58. The company's past performance shows a mixed impact on the share price post-earnings release. The stock was trading at $66.0 as of July 31, with a 52-week return of 8.99%.
August 04, 2023 | 9:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Blueprint Medicines is expected to report an EPS of $-2.58 in its upcoming earnings. The company's past earnings have shown a mixed impact on the share price. The stock has returned 8.99% over the last 52 weeks.
The upcoming earnings report is a significant event for Blueprint Medicines. However, the company's past earnings have shown a mixed impact on the share price, making it difficult to predict the short-term price direction. The stock has shown positive returns over the past year, which could indicate investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100